Meeder Asset Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Meeder Asset Management’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,584	Closed	-$1.74K	–	849
2025 Q1	$1.74K	Buy	+1,584	New	+$2.26K	﹤0.01%	873

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Meeder Asset Management's ABOS Position: Q2 2025 in Review

Meeder Asset Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 1,584 shares — an estimated $1.74K sold.

Meeder Asset Management first reported a position in ABOS in Q1 2025 and held it in 1 quarter. The position peaked at $1.74K in Q1 2025. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

Meeder Asset Management reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Meeder Asset Management sold 1,584 Acumen Pharmaceuticals shares in Q2 2025, an estimated $1.74K.
Meeder Asset Management first reported a position in Acumen Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Meeder Asset Management's Acumen Pharmaceuticals position peaked at $1.74K in Q1 2025.
71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on Meeder Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.